Immunovaccine, PharmAthene to develop anthrax vaccine formulated in Depovax
As part of the deal, both the firms will jointly work to develop an adjuvanted non-alum based rPA vaccine. The deal provides PharmAthene exclusive worldwide rights to use
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).